Frost & Sullivan: High Incidence and Inadequate Treatments Boost Prospects of HIV, Chagas, Dengue and Influenza H1N1 Therapeutics in Latin America

Description

Frost & Sullivan: High Incidence andFrost & Sullivan: High Incidence and Inadequate Treatments Boost Prospects of HIV, Chagas, Dengue and Influenza H1N1 Therapeutics in Latin America PR Newswire BUENOS AIRES, Argentina, March 13, 2014 - Pharmaceutical companies work with governments in the region to increase disease awareness and access to treatment The high incidence of human immunodeficiency virus (HIV), Chagas, dengue and influenza H1N1, as well as the unavailability of adequate treatments for these infectious diseases, spell opportunities for pharmaceutical companies across Latin America to develop new, improved diagnosis and treatment methods. New analysis from Frost & Sullivan (http://www.lifesciences.frost.com), A Product and Pipeline Analysis of the Latin American HIV, Chagas, Dengue, and Influenza H1N1 Therapeutics Markets, finds that Chagas ranks the highest in terms of relative prevalence, and the 50 percent efficacy rate of current treatments means that this is a market to be tapped and developed. HIV has the second-highest incidence rate, followed by dengue and influenza H1N1. "Pharmaceutical companies in Latin America currently offer numerous generic drugs for the treatment of HIV at reduced prices owing to intense competition in the market," stated Frost & Sullivan Healthcare Industry Analyst Lucila Rocca.

Informations

• Publié par: frost-sullivan
• Publié le: 13 mars 2014
• Nombre de lectures: 1
• Langue: English

Extrait

Frost & Sullivan: High Incidence and Inadequate Treatments Boost Prospects of HIV, Chagas, Dengue and Influenza H1N1 Therapeutics in Latin America

PR Newswire

BUENOS AIRES, Argentina, March 13, 2014

- Pharmaceutical companies work with governments in the region to increase disease awareness and access to treatment

The high incidence of human immunodeficiency virus (HIV), Chagas, dengue and influenza H1N1, as well as the unavailability of adequate treatments for these infectious diseases, spell opportunities for pharmaceutical companies across Latin America to develop new, improved diagnosis and treatment methods.